Perbandingan Penggunaan Efavirenz dan Nevirapine Terhadap Kolesterol LDL Pasien HIV/AIDS
Main Authors: | Anggriani, Yusi; Fakultas Farmasi Universitas Pancasila, Yunihastuti, Evy; RSUPN Dr. Cipto Mangunkusumo, Jakarta 10430, Indonesia, Trisna, Yulia; RSUPN Dr. Cipto Mangunkusumo, Jakarta 10430, Indonesia, Rosanti, Ade; RSUPN Dr. Cipto Mangunkusumo, Jakarta 10430, Indonesia, Manninda, Reise; Fakultas Farmasi Universitas Pancasila, Jakarta 12630, Indonesia, Annisa, Rifka; Fakultas Farmasi Universitas Pancasila, Jakarta 12630, Indonesia |
---|---|
Format: | Article info application/pdf Journal |
Bahasa: | eng |
Terbitan: |
Directorate of Research and Community Engagement, Universitas Indonesia
, 2019
|
Subjects: | |
Online Access: |
http://psr.ui.ac.id/index.php/journal/article/view/4225 http://psr.ui.ac.id/index.php/journal/article/view/4225/717 http://psr.ui.ac.id/index.php/journal/article/downloadSuppFile/4225/1239 http://psr.ui.ac.id/index.php/journal/article/downloadSuppFile/4225/1240 |
Daftar Isi:
- AIDS (Acquired Immuno Deficiency Syndrome) is an infectious disease caused by HIV (Human Immunodeficiency Virus). It attacks white blood cells (lymphocytes), it causes lower immune system. A guidelines for HIV/AIDS is antiretroviral treatment. Metabolic disorders are common condition in HIV, either may affect lipid metabolism. Especially for those using first-line ARVs, such as efavirenz and nevirapine. Related to these conditions, then we were did this study to assess LDL cholesterol in HIV/AIDS patiens whose using first line therapy, especially efavirenz and nevirapine. This is prospectively study using comparative design to compare LDL cholesterol between efavirenz and nevirapine. The participants were HIV / AIDS patients who suitable with criteria. After analysis, patients taking efavirenz had 142.31 mg/dL ±41,461 LDL cholesterol, and nevirapine 126.83 mg/dL ±40,556. It means patients on efavirenz has higher LDL cholesterol than nevirapine. However, the difference was not statistically significant, with P= 0.119.